We are live on ! Find out more
PALI icon

Palisade Bio
PALI

6 hedge funds and large institutions have $791K invested in Palisade Bio in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

811% more capital inflows, than outflows

Capital inflows: $1.42M | Capital outflows: $156K

0% more funds holding

Funds holding: 6 → 6 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

4.03% less ownership

Funds ownership: 4.03% → 0% (-4%)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $4K

Holders
6
Holders Change
–
Holders Change %
0%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
$4K
Net Calls
-$4K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$641K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$335K
3
Renaissance Technologies
Renaissance Technologies
New York
+$279K
4
HighTower Advisors
HighTower Advisors
Illinois
+$139K
5
ARTA
A.R.T. Advisors
New York
+$27.9K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$49K
2
Alethea Capital Management
Alethea Capital Management
Washington
-$48K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$27K
4
Citadel Advisors
Citadel Advisors
Florida
-$18K
5
Northern Trust
Northern Trust
Illinois
-$7K

PALI Hedge Fund Activity: Q3 2019 in Review

6 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q3 2019, worth a combined $791K — up 236% from $235K a quarter earlier.

Fund positioning in PALI was balanced in Q3 2019: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $641K. The largest seller was Vanguard Group, exiting entirely with an estimated $49K sold.

  • 6 institutional investors held Palisade Bio (PALI) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $791K of Palisade Bio stock for Q3 2019, up 236% quarter-over-quarter.
  • 4 funds opened new Palisade Bio positions in Q3 2019 and 4 closed out, a net change of 0 holders.
  • The largest Palisade Bio buyer in Q3 2019 was Sabby Management, an estimated $641K added.
  • The largest Palisade Bio seller in Q3 2019 was Vanguard Group, an estimated $49K sold.

Based on aggregated 13F filings for Q3 2019.